{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-000897","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.799678+00:00","generated_at":"2026-06-20T20:07:39.442910+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Innoviva appoints Dr. Sapna Srivastava to board, effective Jan 1, 2023","bullets":["Dr. Sapna Srivastava appointed to Board as independent director, effective Jan 1, 2023.","Srivastava brings experience as former CFO of Intellia Therapeutics and Abide Therapeutics, and 15 years as biotech analyst.","Received initial RSU award of $125,000, prorated RSU of $56,250, and option for 2,500 shares.","Annual cash retainer of $50,000 for board service.","Bylaws amended to remove reference to SmithKline Beecham and update director nomination procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-000897","json":"https://secwatch.observer/filing/0001104659-23-000897.json","markdown":"https://secwatch.observer/filing/0001104659-23-000897.md","text":"https://secwatch.observer/filing/0001104659-23-000897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/tm231444d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:07:39.442910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8440c270ca","claim":"Sapna Srivastava was appointed as Director at Innoviva, Inc..","evidence_excerpt":"On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f5fa02f862b0742d1a5b4f8db3a55e17d659027c","claim":"Innoviva, Inc.: Amended the Company's by-laws to remove reference to SmithKline Beecham Corporation as a shareholder and update procedures and information requirements for director nominations, including with respect to Rule 14a-19 (effective 2023-01-01).","evidence_excerpt":"On December 31, 2022, the Board amended the Company’s by-laws, effective as of January 1, 2023, to remove reference to SmithKline Beecham Corporation, a Pennsylvania corporation, as a shareholder of the Company and update the procedures and information requirements for the nomination of directors, including with respect to Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-01-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}